January 22, 2018
VIA EDGAR
Mr. Jeffrey Gabor
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Melinta Therapeutics, Inc. |
Registration Statement on FormS-3 |
Filed January 9, 2018 |
FileNo. 333-222487 |
Dear Mr. Gabor:
We are responding to the oral comment on January 17, 2018 of the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) pertaining to Melinta Therapeutic, Inc.’s (the “Company”) Registration Statement on FormS-3, filed on January 9, 2018, FileNo. 333-222487 (the “FormS-3”). The Company is concurrently filing Amendment No. 1 to the FormS-3 (the “Amendment”) to respond to the oral comment.
We have set forth the Staff’s oral comment in bold below with the Company’s corresponding response.
1. | Add the following Current Reports on Form8-K to the list of Current Reports on Form8-K incorporated by reference in the prospectus: Current Reports on Form8-K dated February 24, 2017 and December 27, 2017 and the Current Reports on Form8-K/A dated December 6, 2017 and January 10, 2018. |
Response:
In responding to the Staff’s comment, we have revised the disclosure on page 21 to incorporate the above-mentioned Current Reports on Form8-K and Current Reports on Form8-K/A by reference.
Very truly yours,
/s/ Paul Estrem
Paul Estrem
Chief Financial Officer
cc: | Sean M. Ewen, Esq. (Willkie Farr & Gallagher LLP) |
- 2 -